A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Hematopoietic stem cell transplantation in the myelodisplastic syndromes
Trasplante de células progenitoras hematopoyéticas en síndromes mielodisplásicos
Revista de investigación clínica
Trasplante de células progenitoras hematopoyéticas en síndromes mielodisplásicos
Myelodisplastic syndromes (MDS) are clonal hematopoietic disorders, characterized by ineffective hemopoiesis resulting in single or multiple lineages and a high risk of conversion to acute leukemia. Currently, the only established therapy with curative potential for MDS is a hemopoietic stem cell transplant (HSCT). Their results are determined by the type of MDS, age at the BMT and the score according to the international index. In the main studies the disease-free survival (DFS) were 35-43%,
pmid:16524069
fatcat:qll75tsvifbhnbby7ioj2rocci